Clinical Trial Update: Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing irinotecan liposome plus 5-FU/LV versus 5-FU/LV alone as second-line therapy in gemcitabine-refractory pancreatic cancer (locally…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-FU/LV (5-fluorouracil with leucovorin)
• Irinotecan liposome (liposomal irinotecan)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | Phase 3 | Status: COMPLETED